Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.14
- Piotroski Score 5.00
- Grade Outperform
- Symbol (REGN)
- Company Regeneron Pharmaceuticals, Inc.
- Price $828.16
- Changes Percentage (-1.83%)
- Change -$15.44
- Day Low $826.76
- Day High $852.00
- Year High $1,211.20
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/31/2025
- Fiscal Year End N/A
- Average Stock Price Target $1,055.00
- High Stock Price Target $1,300.00
- Low Stock Price Target $604.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $33.83
- Trailing P/E Ratio 29.65
- Forward P/E Ratio 29.65
- P/E Growth 29.65
- Net Income $3.95 B
Income Statement
Quarterly
Annual
Latest News of REGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Doctors say strict abortion laws in Texas put pregnant women and their physicians at serious risk
Following the overturn of Roe v. Wade, 20 states imposed strict abortion laws, while 6 states protected access. Texas' evolving laws led to challenges for women like Dr. Dani Mathisen, whose tragic ex...
By CBS News | 1 day ago -
Texas women facing pregnancy complications are forced to travel out of state for care
Dani Mathisen faced challenges when her daughter's severe abnormalities required an abortion, banned in Texas. She had to seek care in New Mexico due to restrictive laws. After a lawsuit, Texas added ...
By CBS News | 1 day ago -
Pregnant Brittany Mahomes Posts Adorable Video of Son Bronze Trying to Blow on a Dandelion
Kansas City Current co-owner Brittany Matthews shared a cute video on Instagram of her son, Patrick Mahomes III, trying to blow on a dandelion. The toddler, nearly 2, struggled with the task, amusing ...
By PEOPLE.com | 2 days ago
